What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Richard Conway RichardPAConway
3 years 6 months ago
Redondo-Rodriguez et al. Abatacept in RA-ILD. Prospective study 38 patients. 73.6% improved/stablised with abatacept at median 17 month follow-up @RheumNow #EULAR2022 POS0654 https://t.co/D2du0hAXIy
Aurelie Najm AurelieRheumo
3 years 6 months ago
JUVE-BASIS Baricitinib in JIA
Phase 3 RCT wk12
Cs or BioDMARDs IR
⚡️Time to disease flare HR 0.24
⚡️JIA-ACR50% 63%
⚡️% flares 17% vs. 50% in PBO
Safety profile similar than adults
@RheumNow
#EULAR2022 LB0002 https://t.co/dX3DpB4QHT
David Liew drdavidliew
3 years 6 months ago
@EricFMorand up first in late-breakings
PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid wean
Good outcomes:
primary: SRI(4) at 32w
skin/joint/LLDAS & dsDNA/C4
Safety good (like PsO/PsA) but higher dose less so
Watch for: other clinical, ph3
#EULAR2022 @RheumNow https://t.co/XOQWuiHkTx
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#POS1207 #EULAR2022 In N=98 RA patients with poor antibody response to rituximab after two doses, 19% responded after 3rd dose. Associated with longer Time of vaccine from last RTX & interestingly ultra dose 200mg used in the Netherlands @RheumNow https://t.co/TTXXtOU6vp
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 LB0001
Bimekizumab (IL-17F and IL-17A) in bionaive PsA
BE OPTIMAL phase 3 trial, 24 weeks
⭐️Met Primary endpt - ACR50
⭐️Met other ACR and PASI endpts
⭐️Safety: higher fungal infections
@RheumNow https://t.co/x8u6B93FNl
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Who remotely enters PROs online? Glintborg et al from the Danbio Registry showed that patients who used the system were mainly 40-80 years of age, on biologics and had lower HAQ score. Disease duration and diagnosis had no impact, reminders helped #EULAR2022 @RheumNow POS0373 https://t.co/voCfGiJgwm
Richard Conway RichardPAConway
3 years 6 months ago
Fascinating! Richette et al. Machine learning identifies 8 clusters of PsA phenotypes. Treatment responses seem to differ, being better in cluster 2 and worse in cluster 5 and 6 (at least for IL23i guselkumab). @RheumNow #EULAR2022 POS1055 https://t.co/QIh2SbJKpa
Richard Conway RichardPAConway
3 years 6 months ago
Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.co/BjuYj6xUdZ
TheDaoIndex KDAO2011
3 years 6 months ago
Wow! Phase 2 #deucravacitinib data for #SLE met primary & secondary endpoints: SRI(4) response, BICLA, LLDAS, CLASI-50. AEs include: skin related events and UTIs but no increase in SIE, HZ, MACE/VTE @bmsnews LB0004 #EULAR022 @rheumnow https://t.co/bsKI0mixVT
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in Italy (>450 pts) found 1/4 had side effects (mostly mild) and 4% had a flare. These side effects were more common in those on >1 DMARDS and Belimumab @RheumNow https://t.co/mNS6rQfsSq
David Liew drdavidliew
3 years 6 months ago
BRIDGE-PMR (rituximab in PMR) routine care extension to 52w
(in #PMRGCAJC one big qu asked was ?sustained benefit)
sustained benefit (RR 2.5 GC-free remission)
steroid-sparing (PNL 1.6g v 2.3g)
& ritux ?cheap enough now
but COVID calculus difficult
POS0269 #EULAR2022 @RheumNow https://t.co/Ln2ArclKO8 https://t.co/OtCwdjIPeL
Dr. Antoni Chan synovialjoints
3 years 6 months ago
What guides treatment decisions in AxSpA? Bolt et al showed patients assessed in clinical remission, 1/3 had BASDAI >3.5. Treatment unchanged as low disease activity, awaiting effects of current Rx, complaints not related to axSpA, patient preference #EULAR2022 @RheumNow POS0303
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Treatment of active SpA improves depressive symptoms in SpA with HADS-D score reducing. This was greatest for TNFi followed by NSAIDs and csDMARDs. TNFi reduced the proportion of patients (48% to 29%) with depressive symptoms at follow up Webers et al #EULAR2022 @RheumNow POS0304
Richard Conway RichardPAConway
3 years 6 months ago
Morand et al Tyk2i deucravacitinib in SLE. 48-week phase 2 RCT. SRI(4) PBO: 34.4%; DEUC 3 mg BID: 58.2%, P =0.0006; DEUC 6 mg BID: 49.5%, P =0.021; DEUC 12 mg QD: 44.9%, P =0.078. BICLA, LLDAS, CLASI-50, active joint count also+ @RheumNow #EULAR2022 LB0004 https://t.co/MBPc9xQFvG https://t.co/n3GUwl0RtD
Aurelie Najm AurelieRheumo
3 years 6 months ago
BE OPTIMAL Phase 3 RCT
Bimekizumab dual IL17A & F inhibitor in bionaive PsA
⭐️ACR50 wk 16 43.9% vs 10% PBO
⭐️PASI 90 wk 16 61% vs. 3% PBO
⭐️separation from wk 4
Safety: fungal injections BKZ > ADA
@RheumNow
LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb
Poster Hall